A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Etrasimod (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms ELEVATE UC 52
- Sponsors Arena Pharmaceuticals
- 17 Jun 2019 According to an Arena Pharmaceuticals Media release, the first subject has been dosed in this study.
- 22 May 2019 Status changed from not yet recruiting to recruiting.
- 08 May 2019 Status changed from planning to not yet recruiting.